Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.
ApexOnco Front Page
Recent articles
First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
CRB-601 and PF-06940434 fall by the wayside.
The company has ditched a trial of drebuxelimab plus ivonescimab.
BPI-572270 enters clinical trials.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
Persevera is a bust, but Roche hasn’t given up on the front line.
